3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
selpercatinib
2
exemestane
2
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Docetaxel
2
AZD9833
2
tucatinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
entinostat
1
elacestrant
1
atezolizumab
1
alectinib
1
Zoledronic Acid
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
Sodium Chloride
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Imlunestrant
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
STX-478
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled